CA29286M1059
© BusinessWire
22.12.2025
ENGN
LISTED
NASDAQ
enGene Reports Full Year 2025 Financial Results and Provides Business Update
News Preview
enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the full year ended October 31, 2025, and provided a business update.
“We are closing 2025 in a position of strength: enrollment in LEGEND's pivotal cohort is complete and the recent dat...
Themefolio
Profiler
Peergroup
© BusinessWire
02.12.2025
ENGN
LISTED
NASDAQ
enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness
News Preview
enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that the U.S. Food and Drug Administration (FDA) has selected detalimogene voraplasmid (also known as detalimogene and previously EG-70) to participate in the Chemistry, Manufacturing, and Controls (CMC) Developm...
Themefolio
Profiler
Peergroup
© BusinessWire
25.11.2025
ENGN
LISTED
NASDAQ
enGene to Present at the Piper Sandler 37th Annual Healthcare Conference
News Preview
enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that Alex Nichols, Ph.D., Chief Strategy and Operations Officer, will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025, at 12:10 p.m. ET.
A webcast of the presentation can be accessed o...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
13.11.2025
ENGN
LISTED
NASDAQ
enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants
News Preview
enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced the pricing of its previously announced underwritten public offering of 12,558,823 common shares at a public offering price of $8.50 per share and pre-funded warrants to purchase 2,735,295 shares of its common shar...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
12.11.2025
ENGN
LISTED
NASDAQ
enGene Announces Proposed Public Offering of Common Shares
News Preview
enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it has commenced an underwritten public offering of its common shares. All common shares to be sold in the offering will be offered by enGene. In addition, enGene intends to grant the underwriters a 30-day opt...
Themefolio
Profiler
Peergroup
© BusinessWire
11.11.2025
ENGN
LISTED
NASDAQ
Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months
News Preview
enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported additional preliminary data from the pivotal cohort of its ongoing, Phase 2 LEGEND trial of detalimogene voraplasmid (also known as detalimogene and previously EG-70) in high-risk, Bacillus Calmette-Guérin (BCG)-u...
Themefolio
Profiler
Peergroup
© BusinessWire
10.11.2025
ENGN
LISTED
NASDAQ
enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial
News Preview
enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a conference call and webcast tomorrow, November 11, 2025, at 8:00 a.m. ET to discuss new preliminary data from its pivotal cohort in the ongoing LEGEND trial of its novel, non-viral gene therap...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
ENGN
LISTED
NASDAQ
enGene to Participate in Upcoming Investor Conferences
News Preview
enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that management will participate in the following investor conferences in November:
Guggenheim 2nd Annual Healthcare Innovation Conference
Date: Tuesday, November 11, 2025
Time: 12:30 p.m. ET
Stifel 2025 Healthcare Conference
D...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ENGN
LISTED
NASDAQ
enGene Named a BioSpace 2026 Best Places to Work Winner
News Preview
enGene Holdings Inc. (“enGene” or the “Company”) (Nasdaq: ENGN), a clinical-stage, non-viral genetic medicines company, today announced that BioSpace has named the company to its 2026 Best Places to Work. enGene is among 50 U.S. operating employers recognized as one of the most desirable workplaces in the life sciences industry.
“Recognition as...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2025
ENGN
LISTED
NASDAQ
Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms
News Preview
Equity Insider
News Commentary
Issued on behalf of GT Biopharma, Inc.
VANCOUVER, BC, Oct. 7, 2025 /PRNewswire/ -...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2025
ENGN
LISTED
NASDAQ
Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms
News Preview
Equity Insider
News Commentary
Issued on behalf of GT Biopharma, Inc.
VANCOUVER, BC, Oct. 7, 2025 /PRNewswire/ -...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2025
ENGN
LISTED
NASDAQ
Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms
News Preview
Equity Insider
News Commentary
Issued on behalf of GT Biopharma, Inc.
VANCOUVER, BC, Oct. 7, 2025 /CNW/ -- Equit...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
01.10.2025
ENGN
LISTED
NASDAQ
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity awards to four newly-hired employees, including Hussein Sweiti, M.D., MSc, Chief Medical Officer, with a grant date of September 30, 2025. The inducement award for Dr. Sweiti consists...
Themefolio
Profiler
Peergroup
© BusinessWire
30.09.2025
ENGN
LISTED
NASDAQ
enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer
News Preview
enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicine company, today announced that Hussein Sweiti, M.D., MSc, was appointed Chief Medical Officer, effective September 29, 2025.
Dr. Sweiti is a surgical oncologist and physician-scientist with more than 15 years of experience spanning clinica...
Themefolio
Profiler
Peergroup
© BusinessWire
11.09.2025
ENGN
LISTED
NASDAQ
enGene Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral gene therapy company, today announced its financial results for the third quarter ended July 31, 2025, and provided a business update.
“Reaching target enrollment in LEGEND’s pivotal Cohort 1 and securing RMAT designation are important milestones that mar...
Themefolio
Profiler
Peergroup
© BusinessWire
03.09.2025
ENGN
LISTED
NASDAQ
enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort
News Preview
enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral gene therapy company, today announced it has achieved its target enrollment milestone of 100 patients for the pivotal cohort of its ongoing, open-label, multi-cohort Phase 2 LEGEND trial of detalimogene voraplasmid (“detalimogene” and previously EG-70) in p...
Themefolio
Profiler
Peergroup
© BusinessWire
27.08.2025
ENGN
LISTED
NASDAQ
enGene to Participate in Upcoming Investor Conferences
News Preview
enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral gene therapy company, today announced that management will participate in the following investor conferences in September:
2025 Wells Fargo Healthcare Conference
Date: Wednesday, September 3, 2025
Time: 8:45 a.m. ET
H.C. Wainwright 27th Annual Global Investment Confer...
Themefolio
Profiler
Peergroup
© BusinessWire
08.07.2025
ENGN
LISTED
NASDAQ
enGene Announces Board and Leadership Appointments to Support Commercial Readiness
News Preview
enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral gene-based immunotherapy company, today announced the appointment of three new members to its Board of Directors: Philip Astley-Sparke, William Grossman, M.D., Ph.D., and Michael Heffernan, R.Ph. Their combined experience across gene therapy, oncology, cl...
Themefolio
Profiler
Peergroup
© BusinessWire
25.06.2025
ENGN
LISTED
NASDAQ
FDA Grants RMAT Designation for enGene’s Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer
News Preview
enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage, non-viral gene-based immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to detalimogene voraplasmid (also known as detalimogene, and previously EG-70), the C...
Themefolio
Profiler
Peergroup
© BusinessWire
17.06.2025
ENGN
LISTED
NASDAQ
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity awards to four newly-hired employees, including Amy Pott, Chief Global Commercialization Officer, with a grant date of June 16, 2025. The inducement award for Ms. Pott consists of a no...
Themefolio
Profiler
Peergroup
© BusinessWire
12.06.2025
ENGN
LISTED
NASDAQ
enGene Reports Second Quarter 2025 Financial Results and Provides Business Update
News Preview
enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the second quarter ended April 30, 2025, and provided a business update.
“We have seen strong enrollment in the pivotal cohort of our LEGEND study,” said Ron Cooper, Chief Executive O...
Themefolio
Profiler
Peergroup
© BusinessWire
04.06.2025
ENGN
LISTED
NASDAQ
enGene Announces the Resignation of its Chief Medical Officer
News Preview
enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, announced today that Dr. Raj Pruthi resigned from his role as Chief Medical Officer on June 3, 2025. Dr. Pruthi’s resignation as Chief Medical Officer will take effect on June 16, 2025. He will be supporting the organization to...
Themefolio
Profiler
Peergroup
© BusinessWire
29.05.2025
ENGN
LISTED
NASDAQ
enGene to Present at the Jefferies Global Healthcare Conference
News Preview
enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference in New York City on Wednesday, June 4, 2025, at 11:05 a.m. ET.
A live webcast of the presentation can be acce...
Themefolio
Profiler
Peergroup
© BusinessWire
28.05.2025
ENGN
LISTED
NASDAQ
enGene Names Amy Pott as Chief Global Commercialization Officer
News Preview
enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced the appointment of Amy Pott as Chief Global Commercialization Officer. In this role, Ms. Pott will serve as the Company’s first dedicated executive for commercialization planning and execution, reporting to enGen...
Themefolio
Profiler
Peergroup
© BusinessWire
28.04.2025
ENGN
LISTED
NASDAQ
enGene to Participate in Upcoming Investor Conferences
News Preview
enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that management will present at upcoming investor conferences in May 2025. Details of the conferences are below:
Conference: 2025 Bloom Burton & Co. Healthcare Investor Conference
Date: Monday, May 5, 2025
T...
Themefolio
Profiler
Peergroup
© BusinessWire
04.04.2025
ENGN
LISTED
NASDAQ
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity awards to seven newly-hired employees, with a grant date of April 2, 2025. The inducement awards consist of a non-qualified stock options to purchase an aggregate 144,650 of the Compan...
Themefolio
Profiler
Peergroup
© BusinessWire
01.04.2025
ENGN
LISTED
NASDAQ
enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum
News Preview
enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, Chief Executive Officer, will present at the Stifel 2025 Virtual Targeted Oncology Forum, on Tuesday, April 8, 2025, at 4:00 p.m. ET.
A live webcast of the presentation can be accessed under the...
Themefolio
Profiler
Peergroup
© BusinessWire
10.03.2025
ENGN
LISTED
NASDAQ
enGene Reports First Quarter 2025 Financial Results and Provides Business Update
News Preview
enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter ended January 31, 2025, and provided a business update.
“With the expansion of LEGEND study sites into Europe and Asia, enrollment in our pivotal cohort continues to...
Themefolio
Profiler
Peergroup
© BusinessWire
04.03.2025
ENGN
LISTED
NASDAQ
enGene to Participate in the Leerink Partners Global Healthcare Conference
News Preview
enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference, taking place in Miami, FL on Tuesday, March 11, 2025, at 1:00 p.m. ET.
A live w...
Themefolio
Profiler
Peergroup
© BusinessWire
04.02.2025
ENGN
LISTED
NASDAQ
enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
News Preview
enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle inva...
Themefolio
Profiler
Peergroup
© BusinessWire
31.01.2025
ENGN
LISTED
NASDAQ
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle inva...
Themefolio
Profiler
Peergroup
© BusinessWire
30.01.2025
ENGN
LISTED
NASDAQ
enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)
News Preview
enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle inv...
Themefolio
Profiler
Peergroup
© BusinessWire
30.12.2024
ENGN
LISTED
NASDAQ
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle inva...
Themefolio
Profiler
Peergroup
© BusinessWire
19.12.2024
ENGN
LISTED
NASDAQ
enGene Reports Full Year 2024 Financial Results and Provides a Business Update
News Preview
enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle i...
Themefolio
Profiler
Peergroup
© BusinessWire
25.11.2024
ENGN
LISTED
NASDAQ
enGene to Participate in Upcoming Investor Conferences
News Preview
enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle inva...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2024
ENGN
LISTED
NASDAQ
enGene to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
News Preview
enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle inva...
Themefolio
Profiler
Peergroup
© BusinessWire
25.10.2024
ENGN
LISTED
NASDAQ
enGene Announces $60 Million Private Placement Financing
News Preview
enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle inva...
Themefolio
Profiler
Peergroup
© BusinessWire
22.10.2024
ENGN
LISTED
NASDAQ
enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
News Preview
enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle inva...
Themefolio
Profiler
Peergroup
© BusinessWire
21.10.2024
ENGN
LISTED
NASDAQ
enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer
News Preview
enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle inva...
Themefolio
Profiler
Peergroup
© BusinessWire
01.10.2024
ENGN
LISTED
NASDAQ
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News Preview
enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle inva...
Themefolio
Profiler
Peergroup
© BusinessWire
26.09.2024
ENGN
LISTED
NASDAQ
Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort
News Preview
enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), is a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle i...
Themefolio
Profiler
Peergroup
© BusinessWire
10.09.2024
ENGN
LISTED
NASDAQ
enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update
News Preview
enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle i...
Themefolio
Profiler
Peergroup
© BusinessWire
28.08.2024
ENGN
LISTED
NASDAQ
enGene to Participate in Upcoming Investor Conferences
News Preview
enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program detalimogene voraplasmid (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder canc...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
